Medios AG (XTRA:ILM1) entered into a purchase agreement to acquire NewCo Pharma GmbH for approximately €120 million on November 25, 2021. As a par of consideration, Medios will pay €85.2 million in cash and will issue 924,233 new Medios shares. The new Medios shares to be issued will be created from authorized capital in a capital increase against contributions in kind. The remaining purchase price portion will be provided by Medios from existing cash and a committed credit facility. In order to secure the financing of the cash purchase price component, Medios has secured a credit line of €60 million with a short term at market conditions. The consolidated revenue of the NewCo Pharma Group is around €153 million in 2020. The implementation of the acquisition is subject to approval by the German Federal Cartel Office. The German Federal Cartel Office has approved the transaction on December 14, 2021. The closing of the transaction is planned for the first quarter of 2022.

Medios AG (XTRA:ILM1) completed the acquisition of NewCo Pharma GmbH on January 11, 2022. All closing conditions have been met.